Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 313

1.

Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation.

Pico de Coaña Y, Wolodarski M, Gentilcore G, Yoshimoto Y, Poschke I, Hansson J, Masucci GV, Kiessling R.

J Transl Med. 2015;13:2064. doi: 10.1186/1479-5876-13-S1-O7. No abstract available.

2.

TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.

Jangard M, Zebary A, Ragnarsson-Olding B, Hansson J.

Melanoma Res. 2015 Mar 5. [Epub ahead of print]

PMID:
25746036
3.

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy.

Schwaederlé M, Lazar V, Validire P, Hansson J, Lacroix L, Soria JC, Pawitan Y, Kurzrock R.

Cancer Res. 2015 Feb 11. [Epub ahead of print]

PMID:
25672981
4.

BRAFV600E Protein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases.

Eriksson H, Zebary A, Vassilaki I, Omholt K, Ghaderi M, Hansson J.

JAMA Dermatol. 2015 Jan 14. doi: 10.1001/jamadermatol.2014.3689. [Epub ahead of print]

PMID:
25588152
5.

Heart block and acute kidney injury due to hyperparathyroidism-induced hypercalcemic crisis.

Brown TC, Healy JM, McDonald MJ, Hansson JH, Quinn CE.

Yale J Biol Med. 2014 Dec 12;87(4):563-7. eCollection 2014 Dec.

6.

Transcriptome-wide profiling and posttranscriptional analysis of hematopoietic stem/progenitor cell differentiation toward myeloid commitment.

Klimmeck D, Cabezas-Wallscheid N, Reyes A, von Paleske L, Renders S, Hansson J, Krijgsveld J, Huber W, Trumpp A.

Stem Cell Reports. 2014 Nov 11;3(5):858-75. doi: 10.1016/j.stemcr.2014.08.012. Epub 2014 Sep 25.

7.

Microfluidic-based isolation of bacteria from whole blood for sepsis diagnostics.

Zelenin S, Hansson J, Ardabili S, Ramachandraiah H, Brismar H, Russom A.

Biotechnol Lett. 2015 Apr;37(4):825-30. doi: 10.1007/s10529-014-1734-8. Epub 2014 Nov 21.

PMID:
25413883
8.

MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.

Tuominen R, Jewell R, van den Oord JJ, Wolter P, Stierner U, Lindholm C, Hertzman Johansson C, Lindén D, Johansson H, Frostvik Stolt M, Walker C, Snowden H, Newton-Bishop J, Hansson J, Egyházi Brage S.

Int J Cancer. 2014 Nov 15. doi: 10.1002/ijc.29332. [Epub ahead of print]

PMID:
25400033
9.

Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men.

Lyth J, Eriksson H, Hansson J, Ingvar C, Jansson M, Lapins J, Månsson-Brahme E, Naredi P, Stierner U, Ullenhag G, Carstensen J, Lindholm C.

Br J Dermatol. 2015 Mar;172(3):700-6. doi: 10.1111/bjd.13483. Epub 2015 Feb 5.

PMID:
25323770
10.

Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels.

Vihinen P, Tervahartiala T, Sorsa T, Hansson J, Bastholt L, Aamdal S, Stierner U, Pyrhönen S, Syrjänen K, Lundin J, Hernberg M.

Cancer Immunol Immunother. 2015 Feb;64(2):173-80. doi: 10.1007/s00262-014-1620-1. Epub 2014 Oct 16.

PMID:
25319807
11.

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K.

N Engl J Med. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037. Epub 2014 Sep 29.

PMID:
25265492
12.

The effect on melanoma risk of genes previously associated with telomere length.

Iles MM, Bishop DT, Taylor JC, Hayward NK, Brossard M, Cust AE, Dunning AM, Lee JE, Moses EK, Akslen LA; AMFS Investigators, Andresen PA, Avril MF, Azizi E, Scarrà GB, Brown KM, Dębniak T, Elder DE, Friedman E, Ghiorzo P, Gillanders EM, Goldstein AM, Gruis NA, Hansson J, Harland M, Helsing P, Hočevar M, Höiom V; IBD investigators, Ingvar C, Kanetsky PA, Landi MT, Lang J, Lathrop GM, Lubiński J, Mackie RM, Martin NG, Molven A, Montgomery GW, Novaković S, Olsson H, Puig S, Puig-Butille JA; QMEGA and QTWIN Investigators, Radford-Smith GL, Randerson-Moor J; SDH Study Group, van der Stoep N, van Doorn R, Whiteman DC, MacGregor S, Pooley KA, Ward SV, Mann GJ, Amos CI, Pharoah PD, Demenais F, Law MH, Newton Bishop JA, Barrett JH; GenoMEL Consortium.

J Natl Cancer Inst. 2014 Sep 17;106(10). pii: dju267. doi: 10.1093/jnci/dju267. Print 2014 Oct.

13.
14.

Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation.

Hergens MP, Galanti R, Hansson J, Fredlund P, Ahlbom A, Alfredsson L, Bellocco R, Eriksson M, Fransson EI, Hallqvist J, Jansson JH, Knutsson A, Pedersen N, Lagerros YT, Ostergren PO, Magnusson C.

Epidemiology. 2014 Nov;25(6):872-6. doi: 10.1097/EDE.0000000000000169.

PMID:
25166877
15.

Identification of regulatory networks in HSCs and their immediate progeny via integrated proteome, transcriptome, and DNA Methylome analysis.

Cabezas-Wallscheid N, Klimmeck D, Hansson J, Lipka DB, Reyes A, Wang Q, Weichenhan D, Lier A, von Paleske L, Renders S, Wünsche P, Zeisberger P, Brocks D, Gu L, Herrmann C, Haas S, Essers MA, Brors B, Eils R, Huber W, Milsom MD, Plass C, Krijgsveld J, Trumpp A.

Cell Stem Cell. 2014 Oct 2;15(4):507-22. doi: 10.1016/j.stem.2014.07.005. Epub 2014 Aug 21.

PMID:
25158935
16.

Feasibility of ballistic strengthening exercises in neurologic rehabilitation.

Williams G, Clark RA, Hansson J, Paterson K.

Am J Phys Med Rehabil. 2014 Sep;93(9):828-33. doi: 10.1097/PHM.0000000000000139.

PMID:
25137195
17.

Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial.

Olofsson R, Ny L, Eilard MS, Rizell M, Cahlin C, Stierner U, Lönn U, Hansson J, Ljuslinder I, Lundgren L, Ullenhag G, Kiilgaard JF, Nilsson J, Lindnér P.

Trials. 2014 Aug 9;15:317. doi: 10.1186/1745-6215-15-317.

18.

Fine mapping of genetic susceptibility loci for melanoma reveals a mixture of single variant and multiple variant regions.

Barrett JH, Taylor JC, Bright C, Harland M, Dunning AM, Akslen LA, Andresen PA, Avril MF, Azizi E, Bianchi Scarrà G, Brossard M, Brown KM, Dębniak T, Elder DE, Friedman E, Ghiorzo P, Gillanders EM, Gruis NA, Hansson J, Helsing P, Hočevar M, Höiom V, Ingvar C, Landi MT, Lang J, Lathrop GM, Lubiński J, Mackie RM, Molven A, Novaković S, Olsson H, Puig S, Puig-Butille JA, van der Stoep N, van Doorn R, van Workum W, Goldstein AM, Kanetsky PA, Pharoah PD, Demenais F, Hayward NK, Newton Bishop JA, Bishop DT, Iles MM; GenoMEL Consortium.

Int J Cancer. 2015 Mar 15;136(6):1351-60. doi: 10.1002/ijc.29099. Epub 2014 Aug 14.

19.

Primary melanoma tumors from CDKN2A mutation carriers do not belong to a distinct molecular subclass.

Staaf J, Harbst K, Lauss M, Ringnér M, Måsbäck A, Howlin J, Jirström K, Harland M, Zebary A, Palmer JM, Ingvar C, Olsson H, Newton-Bishop J, Hansson J, Hayward N, Gruis N, Jönsson G; Melanoma Genetics Consortium.

J Invest Dermatol. 2014 Dec;134(12):3000-3. doi: 10.1038/jid.2014.272. Epub 2014 Jul 7. No abstract available.

PMID:
24999598
20.

A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.

Poschke I, Lövgren T, Adamson L, Nyström M, Andersson E, Hansson J, Tell R, Masucci GV, Kiessling R.

Cancer Immunol Immunother. 2014 Oct;63(10):1061-71. doi: 10.1007/s00262-014-1575-2. Epub 2014 Jul 4.

PMID:
24993563
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk